Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summit's Biologics License Application (BLA) seeking ...
High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, ...
The Institute of Cancer Research has welcomed NICE’s recommendation of talazoparib in combination with enzalutamide for adults with metastatic prostate cancer, providing a new treatment option for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results